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Abstract
Since extracellular vesicles (EVs) were discovered in 1983 in sheep reticulocytes samples, they
have gradually attracted scientific attention and become a topic of great interest in the life
sciences field. EVs are small membrane particles, released by virtually every cell that carries a
variety of functional molecules. Their main function is to deliver messages to the surrounding
area in both physiological and pathological conditions. Initially, they were thought to be either
cell debris, signs of cell death, or unspecific structures. However, accumulating evidence
support a theory that EVs are a universal mechanism of communication. Thanks to their
biological characteristics and functions, EVs are likely to represent a promising strategy for
obtaining pathogen information, identifying therapeutic targets and selecting specific
biomarkers for a variety of diseases, such as autoimmune diseases.
In this review, we provide a brief overview of recent progress in the study of the biology and
functions of EVs. We also discuss their roles in diagnosis and therapy, with particular emphasis
on autoimmune diseases.
Key words: Extracellular vesicles; autoimmune diseases; biomarkers; communication; therapy.

Introduction
Extracellular vesicles (EVs) are broadly classified
in three sub-classes, depending on their biogenesis
and size, exosomes (10-100nm); microvesicles (MVs),
also called ectosomes, (100-1000nm); apoptotic bodies
(1000-5000 nm) [1]. However, even if this
nomenclature is extensively used, the classification of
these heterogeneous populations of EVs is still a
matter of debate [2]. Our initial understanding of EVs
originated from exosomes found in sheep
reticulocytes in 1983 [3]. EVs represent a direct means
of cellular communication [1]. They thus play an
important role in the development and regulation of
many biological processes [4]. They carry proteins,

DNA and various RNAs: mRNAs, miRNAs, long
non-coding RNAs (lncRNAs), circular RNAs
(circRNAs), all involved in intracellular signal
transduction [5]. New research evidence suggests that
mitochondria may also be contained in EVs, and that
these mitochondria are capable of inducing epigenetic
modifications of target cells in target organs, such as
mesenchymal stem cells (MSCs) altering the
macrophage
phenotype
by
EVs-mediated
mitochondrial transfer [6]. To induce an effect, EVs
must interact with target cells, either directly with the
plasma or with the endosomal membrane after
cellular uptake [1]. Thus far, different mechanisms for
http://www.ijbs.com
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EVs uptake have been proposed [7].
Given that, theoretically, every cell in the body
releases EVs and that in pathological conditions their
amount may increase, they represent an excellent
biomarker for several diseases [5]. In fact, thanks to
their properties, EVs can be detected in many
different biological fluids such as blood, saliva, urine,
semen, bile, cerebrospinal fluid (CSF), amniotic fluid,
ascites and breast milk [8-10]. Finally, thanks to their
biological characteristics, the idea of using EVs as a
therapeutic delivery vehicle in many applications has
recently emerged [11]. Indeed, the ability to deliver
molecules in different biological districts hardly
accessible such as central nervous system (CNS),
without showing immunogenicity, candidates EVs as
future therapy. So far, several approaches using EVs
as therapy have been proposed [12-15], and many of
them have shown promising results in animals, giving
chances to use them in humans [16]. At present, there
are 477 clinical trials underway using EVs in different
pathologies according to https://clinicaltrials.gov.
We have summarized a portion of the clinical trials
related to EVs in Table 1.

The biogenesis of Extracellular Vesicles
The biogenesis of EVs is similar but not exactly
the same [9]. Exosomes are the smallest particles and
are mainly composed of ceramide, a lipid produced
from sphingosine [1]. Exosomes are formed
intracellularly via endocytic invagination (early and
late endosomes) and are released into a structure
known as the multivesicular body (MVB), resulting in
the progressive accumulation of intraluminal vesicles
(ILVs) [5]. The MVB can undergo lysosome
acidification and destruction or fusion with the
plasma membrane, releasing its cargo of exosomes a
mechanism regulated by Rab GTPases proteins [17,
18]. Endosomal sorting complexes required for

transport (ESCRT) is a mechanism of ILVs or MVB
production [19]. ESCRT is a protein complex located
on the cytoplasmic side of the endosome; its main
function is to sort cell components into ILVs, forming
the precursor of the exosomes. ESCRT contains four
main complexes (ESCRT-0, I, II, III) and accessory
proteins (such as vacuolar protein sorting 4, VPS4;
vesicle trafficking 1, VTA1; ALG-2 interacting protein
X, ALIX), all involved in exosomes biogenesis [20].
The ESCRT complex functions in a certain order. First,
ESCRT-0 and ESCRT-I limit the ubiquitinated
transmembrane cargo subunits to the micro-domains
of MVE or ILVs, while causing deformation of the
membrane structure, ESCRT-II is then used to recruit
ESCRT-III for the budding and scission of this
micro-domain [21, 22]. The classical ESCRT pathway
interacts with syntenin and the ESCRT accessory
protein ALIX, and bridges the ESCRT-III subunit
VPS32, ultimately performing the scission function of
the vesicles to form a closed vesicle [21]. The protein
of the tetraspanin family is involved in the sorting of
vesicle contents [21].
Microvesicles are the EVs class that has been the
least studied and thus far we know very little about
their biogenesis. They are usually larger than
exosomes, depending on the cell type [1]. MVs are
released by the direct budding or protrusion of the
plasma membrane. They typically originate at the
plasma membrane in the region called lipid rafts,
which are membrane domains rich in cholesterol and
glycosphingolipids [23]. The formation of MVs
primarily involves membrane components and the
cytoskeleton [9]. Moreover, during MVs formation
there is externalization of the phospholipid
phosphatidylserine (PS) [24], which normally resides
exclusively in the inner layer of the plasma membrane
[18].

Table 1. Clinical trials related to EVs.
Condition or disease
Type1 Diabetes Mellitus Type2 Diabetes Islet Cell Transplantation
Smoker
Blood Coagulation Disorders
Bronchopulmonary Dysplasia
Coronary Artery Disease Ischaemic Heart Disease Angina Pectoris
Cancer
Cerebrovascular Disorders
Ulcer
Pancreatic Cancer
Colon Cancer
Sarcoma
Lymphoma
Cirrhosis

Origen of EVs
Blood
Human broncho alveolar lavages
Bone marrow
Bone marrow mesenchymal stem cell
Blood
Blood
Mesenchymal stem cell
Plasma
Venous blood
Plant
Blood
Blood
Hepatocyte

Type of EVs
EVs
EVs
EVs
EVs
EVs
EVs
Exosomes
Exosomes
Exosomes
Exosomes
Exosomes
Exosomes
MVs

Phase
ND
ND
ND
Phase 1
ND
ND
Phase 2
Phase 1
ND
Phase 1
ND
ND
ND

NCT number
NCT03106246
NCT03608293
NCT00086476
NCT03857841
NCT03674255
NCT03262311
NCT03384433
NCT02565264
NCT03821909
NCT01294072
NCT03800121
NCT03985696
NCT03837444

ND: Not Determined.
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Table 2. Composition of exosomes and microvesicles.
Composition
Proteins

Exosomes
MVB formation: ALIX, TSG101; Tetraspanins: CD9, CD63, CD81,CD82;
Membrane transport and fusion: annexins, flotillins, GTPases;
Adhesion: integrins; Antigen presentation: MHC class molecules; Heat
shock proteins: HSC70, HSP90; Adaptor protein: Syntenin-1

Lipids

Ceramide; Cholesterol; Phosphatidylserine; Sphingolipids

Nucleic acids

mRNA; miRNA; Non-coding RNA; DNA

Microvesicles
Matrix metalloproteinases; Tetraspanins: CD9, CD63;
Glycoproteins: GPIb, GPIIb-IIIa, P-selectin; Integrins: Mac-1;
Receptors: EGFRvIII; Cytoskeletal components: β-actin and
α-actinin-4; Antigen presentation: MHC class molecules;
Heat shock proteins: HSC70, HSP90
Phosphatidylcholine; Sphingomyelin;
Phosphatidylethanolamine; Lysophospholipids
mRNA; miRNA; Non-coding RNA; DNA

Table 3. The potential protein markers of exosomes and microvesicles.
Markers
Shared markers

Exosomes
ALIX; TSG101; CD81; Syntenin-1; ADAM 10; EHD-4; Annexin XI
Hsc70; Hsp90; Flotillin-1; Annexin II; MHC I; MHC II; CD9; CD63; Actin; Ezrin; Moesin

Currently, no protein markers have been
identified for distinguishing exosomes and MVs
clearly. However, it has been extensively
demonstrated that exosomes fractions are enriched by
Alix, tumor susceptibility gene 101 (TSG101), CD81,
and syntenin-1 proteins, whereas MVs fractions are
enriched by integrins, metalloproteinases, and high
levels of PS exposed to the outer membrane leaflet [2,
25]. Hence, the following two tables summarize the
differences in composition and potential protein
markers for different classes of EVs. Table 3 is based
on the work of Kowal J et al., which combines
gradient centrifugation with iodixanol gradients to
separate different sizes of EVs (light sEV, dense sEV,
large EVs) and perform western blot (WB) detection
[26]. Dissimilarly, Yusuke Y et al. performed WB
detection on the total EVs obtained by
ultracentrifugation of 9 different cells, analyzed the
abundance of different kinds of conventional protein
markers in the cell lysates and corresponding total
EVs [27]. The results indicated that CD9 and CD81 are
highly enriched in various EVs regardless of the
corresponding protein abundance in parent cells. This
slightly different result may be due to differences in
the methods of extraction and comparison of WB,
which also reminds us that various types of EVs need
to be standardized protein markers.
As for the release of EVs, a small fraction of EVs
will be dissolved in the extracellular fluid with their
cargoes, while most of them will interact with specific
types of cells. This interaction is not random, but
depends on the expression of some specific receptors
on the cell surface, although these receptors are not
fully identified [28, 29]. Moreover, the interaction of
most EVs with this specific cell occurs not only near
the release site, but also at regions far away from it.
Through this interaction, a portion of EVs will bind
directly to cell surface receptors, while others will
activate receptors to trigger intracellular signaling,

Microvesicles
Actinin-4; GP96; Mitofilin

some that bind to the receptor and fuse with the target
cell membrane, and then release the cargo into the
cytoplasm; another portion of EVs will enter the cell
by reverse extracellular fusion of the target cell
membrane, this fusion occurring on the surface or
being internalized by endocytosis or phagocytosis.
Once endocytosed or phagocytosed, EVs can be
degraded and their components captured by cells for
their own physiology. When these cargoes are mixed
with local molecules, they participate in the
production of other EVs that are similarly released or
fused to other cells. This process is defined as a
recycling of intercellular communication [28-30].

EVs isolation and characterization methods
In the last few years, many techniques for EVs
isolation and characterization have been described in
the literature, many of which, however, have not been
well standardized [31]. To address this issue, the
International Society for Extracellular Vesicles (ISEV)
has published a paper on the minimal experimental
requirements for definition of EVs and their function
(MISEV) [32]. We list below the methods most widely
used in EVs experimentation.
Isolation: (1) Ultracentrifugation, including
differential centrifugations for isolating different EVs
fractions, is by far the primary isolation method in
EVs application [31]. It removes cells and debris
under low centrifugal force (300 ×g ~ 2000 ×g) and
collects EVs under high centrifugal force (110000 ×g).
The disadvantage is that the instrument is expensive,
the extraction takes time and effort, and the purity is
low. (2) Density gradient is used for isolating different
fractions according to their different density. It is a
more rigorous method than ultracentrifugation and is
usually used to separate exosomes because of its high
purity characteristics, but it cannot meet the
requirements of large amount of samples [33]. (3)
Co-precipitation technique relies on the ability of the
customized polymer to co-precipitate EVs at lower
http://www.ijbs.com
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centrifugation rates [34, 35]. This method easily causes
co-precipitation of non-EVs components and greatly
reduces the purity of EVs. Although commercial kits
have been developed, they are still not suitable for
large-scale use. (4) Size exclusion-chromatography
(SEC) takes advantage of the principle of gel
chromatography and the EVs are mainly purified by
weight or size, it has a high yield but low specificity
[34, 35]. Although these methods represent the most
suitable ones proposed thus far, there is uncertainty
about their application and efficacy in clinic, where
the source of EVs samples is very often limited.
The most commonly used method is
ultracentrifugation, Ludwig AK et al. combined
polyethylene glycol (PEG) co-precipitation and
ultracentrifugation to obtain EVs from cell culture
supernatants, which can obtain ideal EVs in large
quantities without affecting the results of in vivo
experiments[36]. This method also optimizes the
shortcomings of PEG co-precipitation and has
reproducibility and scalability, but the final product
still contain several non-EV related molecules, which
are less pure than size exclusion chromatography and
sucrose density gradient centrifugation. At present,
microfluidic filtering techniques are considered the
most promising strategies for EVs separation in clinic
based on their expandable flux, high degree of
automation, and solid reproducibility [34, 37]. Liu C et
al. introduced a method for EV purification by
microfluidic filtering combined with droplet
enzyme-linked immunosorbent assay (ELISA), which
fills the gap in accurate quantification of EVs [38]. Wu
et al. introduced a method based on the acoustic
principle combined with microfluidic technology
whereby it would become relatively simple to isolate
EVs from whole blood, in a label-free and contact-free
manner that would protect the peculiarities,
structures and functions of isolated EVs [39]. Another
novel technique for EVs purification proposed by
Kabe et al. [40], consists of a high sensitivity and
linearity method from human serum using the
properties of magnetic nanobeads and optical disc
technology.
Characterization: WB remains by far the
common used method for characterizing EVs; also, in
this case, the ISEV has published guidelines for the
identification of EVs, using antibody for proteins like
CD63, CD9, CD81, TSG101, HSP70, Alix [9]. For
studying EVs size and morphology, reliable methods
are electron microscopy (EM) techniques such as
transmission electron microscopy (TEM), scanning
electron microscopy (SEM), Cryo-electron microscopy
(Cryo-EM), and atomic force microscopy (AFM).
Confocal fluorescence microscopy (CFM) is another
advantageous technique for studying the interaction
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between EVs and cells [41-43]. This technique has
resulted very convenient to study the internalization
of EVs by recipient cells [42-46]. Mrinali et al.
developed an innovative method that combines
formalin with 1-ethyl-3-(3-dimethyl aminopropyl)
carbodiimide (EDC) to improving EV imaging in situ.
This approach avoids the traditional formalin-based
technique, which may reverse cross-linkage due to
temperature and allow EVs to escape from the tissue,
resulting in a negative or low signal [47]. Therefore,
this technology has dramatically improved EVs
studies related to basic science, and perhaps, it will be
used for clinical studies. Furthermore, Nanoparticle
Tracking Analysis (NTA) and Tunable Resistive Pulse
Sensing (TRPS) are common techniques for EVs
quantification and size distribution [48]. NTA is able
to track the scattering of individual vesicles over time,
while TRPS is the change in the instantaneous current
when the vesicles pass through the pores [49, 50].
According to the work of Akers JC et al, exosomes are
more suitable for NTA, and MVs is more suitable for
TRPS [51]. Flow Cytometry is also a widely use
method for characterization and quantification [52],
especially now that there is a new fluorescence
activated cell sorting machine with a detection limit
around 100 nm (Cytoflex) [34].

EVs as therapy
Our current knowledge on EVs provides
opportunities for their use in therapy. The relevance
of EVs as a therapeutic tool, already established in the
last few years, is still growing and promising
important developments for the near future. Many
approaches have already been developed [5, 12, 35,
53-55]. EVs act an important role in the therapeutic
effect of MSCs and are therefore considered as a
potential alternative to MSCs. Thus, MSC-derived
EVs (MSC-EVs) would induce a regulatory response
in the function of T-, B-, and monocyte-derived
dendritic cells [56]. In the present work, MSC-EVs
have been shown to possess immunomodulatory
functions which promote B cell activation, induction
of Breg and B cell proliferation was compared to that
the whole MSCs [57]. Fujii et al., showed EVs derived
from BM-NSCs have potential therapeutic effect on
acute graft versus host disease (GVHD) and indicated
the EVs probably inhibit the effector T cell induction
and kept circulating naïve T cells [58]. However, EV
usually does not treat as well as the cell itself, and its
biological effects may be affected by the surrounding
microenvironment [59]. In this case, Milad et al.,
found exosomes derived from MSCs stimulated by
IFN-γ displayed a superior therapeutic effect
compared with native exosomes. This study indicated
that MSCs activated by IFN-γ, which promote
http://www.ijbs.com
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IFNγ-Exo loaded more immunosuppressive cytokine
indoleamine 2,3 -dioxygenase (IDO) resulted in
peripheral blood mononuclear cells (PBMCs)
proliferation
disability.
Therefore,
this
“pre-stimulation” of EVs greatly enhances its
therapeutic effect and represents a new approach for
treatment.
The most intriguing aspect of EVs to have
attracted the scientific interest is the possibility of
customizing them “ad hoc” [13]. This means loading
EVs
with
different
functional
molecules
simultaneously [60], targeting EVs membrane for
increasing tissue and cell targets [61]. We list here the
most recent and promising studies published so far.
Kamerkar et al. engineered exosomes (named in the
paper iExosomes) to specifically target pancreatic
cancer cell-associated KRAS mutant genes, delivering
RNAi and CD47 on exosomes [55]. Directly specific
targeting of KRAS was not possible to achieve before
this study. On the other hand, Kumar et al.
demonstrated an approach whereby EVs are
encapsulated by a 10 nm thick protective film formed
by a supramolecular complex of ferric ions and tannic
acid to achieve non-essential EVs loss, and the
protective film can be fused with other molecules as
targeted delivery while the protective film is also
subject to controlled degradation [62]. Longatti et al.
published a method for specifically targeting
exosomes membrane, with a single-chain variable
fragment of antibody [63]. Recently, Jia G et al.
demonstrated a method for treating glioma cells,
using a click chemistry method to engineer exosomes
with neuropilin-1 peptide and load them with
curcumin [60]. Similarly, Tian et al. used a strategy for
treating murine ischemia targeting exosomes with
c(RGDyK) peptide [13].
However, there are still two problems that need
to be solved: the methods for loading drugs into EVs
cannot guarantee high loading efficiency [64], and, as
a therapeutic medium, EVs cannot be targeted to the
lesion area very well for therapeutic effects [65]. Thus,
improving the EVs loading and delivering efficiency
is one aspect that has been reconsidered, due to a
discrepancy in the published protocol and data
reproducibility [66]. Piffoux et al. published a method
for loading EVs using liposomes and showed
impressive results [67]. However, the efficacy of this
protocol has not been confirmed.
In
the
diagnosis
and
treatment
of
graft-versus-host disease (GVHD), the application of
EVs has made more advancement. The EVs isolated
from patient serum contains three miRNAs (miR-423,
miR-199, miR-93), which may be related to the
incidence and severity of GVHD [68]; and the
expression of CD146, CD31, and CD140-α on EVs
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surface, is also closely related to the onset of the
disease [69]. Traditional MSCs therapy after
replacement with EVs for GVHD also showed ideal
results, suggesting that MSCs-derived EVs are
potential for cell-free therapy for GVHD [58, 70].
Kordelas L et al. used MSCs-derived EVs instead of
MSCs in the patient with GVHD, and the promising
results were obtained. MSCs-derived EVs provide a
potentially viable method for refractory GVHD [71].
In other diseases, such as cancer, EVs also bring
new opportunities for treatment, prevention or
diagnosis. Some studies have found that proteins or
nucleic acid components in EVs can inhibit tumor
development [72], which may be a direct influence or
through antigen presentation to immune cells. For
example, DCs loaded with exosomes and alphagalactosylceramide can significantly improve the
tumor microenvironment of rats bearing gliomas and
increase the median survival of rats [73]. In contrast,
hepatocellular carcinoma-derived exosomes miR-21
are thought to convert normal hepatic stellate cells to
cancer-associated fibroblasts, thereby promoting
tumor progression, which may provide new targets
for the prevention and treatment of liver cancer [74].
The latest evidence suggests that the ability of EVs to
tissue regeneration is equally astonishing. Human
perivascular stem cell-derived EVs can mediate bone
repair [75], and endothelial cell-derived exosomes can
induce angiogenesis in ischemic myocardium [75],
MSCs-derived EVs are important mediators of
cartilage repair, which will have great application
prospects as a therapeutic drug for cartilage
regeneration and osteoarthritis [76].

Extracellular vesicles as biomarkers of
autoimmune disease
In the CNS, EVs have been observed in the
cerebrospinal fluid, indicating their involvement in
many autoimmune diseases, such as multiple
sclerosis (MS) [77] and neuromyelitis optica [78]. They
may play important roles in several biological
processes such as cell-to-cell communication, immune
system response, and nerve degeneration [79-81]. In
MS, Verderio et al. showed that the number of
myeloid EVs was enhanced. These myeloid-derived
EVs were considered as diseases marker which
separation from plasma and can be used to monitor
disease progress [77, 82]. Similar works were also
proved from plasma and serum and indicated EVs
could provide useful information for disease
diagnosis. However, serum has been questioned as a
biomarker recently. The main comment is that
PS-positive MVs in serum are consumed during the
promotion of coagulation, and the remaining MVs do
not reflect overall MVs levels; platelets also release
http://www.ijbs.com
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MVs after activation in coagulation; what’s more, the
presence of thrombin will also influence MVs surface
proteins [83]. In summary, plasma rather than serum
can lead to more convincing results [84].
Urine is another biological fluid commonly used
for new biomarkers assess due to the noninvasive
collection approach. Recently, the composition of
exosomal miRNA was determined by deep
sequencing and several stable expression miRNA
were confirmed as biomarkers, which has verified the
notion of urinary exosomes as a stable source of
miRNA biomarkers for renal fibrosis [85]. Thus, EVs
may be a novel biomarker that will soon replace
biopsies.
There is also evidence that miRNA production
and transport are associated with autoimmune
diseases, especially MS [86]. EVs contain a large
amount of miRNA, which is the main carrier of
circulating miRNAs [86], and the EVs content in
patients' blood is also different from that of healthy
controls [87]. This thus demonstrates that miRNAs in
EVs are a potential biomarker for the diagnosis of MS.
At the same time, it also sets forth requirements for
the standardization of miRNA collection methods.
Recently, the results of sequencing the total
circulating exosomes transcriptome in patients with
relapsing-remitting MS compared with healthy
controls also confirmed that exosomal miRNA is very
helpful as a biomarker for patients with MS [88]. In
the table below, we summarize some of the recent
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studies on EVs as biomarkers in autoimmune
diseases.

EVs play an important role in autoantigen
presentation and T cell modulation
Given that EVs express peptide-MHC
complexes, they may present antigens and activate
immune cell-response [16]. EVs, in particular,
exosomes, have been investigated in antigen
presentation. Exosomes released by antigenpresenting cells (APC) may express class I and II
MHC molecules and co-stimulation molecules and
thus, theoretically, activate CD8+ and CD4+ T
lymphocytes [89]. There are three major mechanisms
for EVs to participate in autoantigen presentation.
EVs participate in autoantigen presentation process
involved in autoimmunity is shown in Fig. 1.
Firstly, exosomes might act indirectly from APCs
uptaking/stimulation [90]. This mechanism appears
more relevant for naïve T cell activation. Eventually,
costimulatory molecules expressed by APCs provide
a necessary second signal for activating T
lymphocytes.
Secondly, the exosomes can be internalized by
APCs and then present antigen to the surface to form
a MHC complex [91, 92]. Once internalized by the
APCs, the complex peptide/MHC will be exposed to
the membrane. Finally, this complex will be involved
in T lymphocytes activation.

Figure 1. Roles of EVs in autoantigen presentation response.

http://www.ijbs.com
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Table 4. EVs as a biomarker in autoimmune disease.
EVs Origin
Serum
Urine
Urine
Serum
CSF
Serum
Serum
Synovial fluid
Saliva
Eosinophils
CFS
Platelets, total
leukocytes or
monocytes
Serum
Urine

Classification
Exosomes
Exosomes
Exosomes
Exosomes
Microvesicles
Exosomes
Exosomes
EVs
Exosomes
Exosomes
Exosomes
Microparticles

Components
Circulating exosomes
miR-146a
miR-29c
Total exosomes
Total microvesicles
miRNA
Hotair
miR-155
miRNA
Total exosomes
Total exosomes
Total microparticles

Change
↑
↑
↓
↑
↑
↓
↑
↑
/
↑
↑
↑

Disease
Systemic lupus erythematosus
Systemic lupus erythematosus
Lupus nephritis
Non-obese diabetes
Multiple sclerosis
Multiple sclerosis
Rheumatoid arthritis
Rheumatoid arthritis
Sjögren's syndrome
Asthma
Multiple sclerosis
Multiple sclerosis

Reference
[147]
[148]
[85]
[149]
[77]
[88]
[150]
[115]
[151]
[152]
[153]
[87]

Exosomes
Microparticles

Myelin protein
Total microparticles

↑
↑

Multiple sclerosis
Type 1 Diabetes

[154]
[155]

autoantigen presentation response.

Thirdly, the study of the immunostimulatory
capacity of APC-derived EVs is still a matter of
debate. Some groups have shown that EVs can
directly activate T cells [93], while others have shown
that EV-dependent T cells stimulation is not enough
and still requires APCs participation [94].
There are few studies on EVs release in T cell
immune regulation mechanisms, but some reports
have demonstrated its importance. It is noteworthy
that regulatory T cells (Treg)-derived EVs could
promote other T cells polarized to the Treg phenotype
[95]. In addition, Treg effectively exocytosed
immunosuppressive EVs that suppressed IFN-γ
production and the proliferation of Th1 cells [96].
Similarly, EVs from endothelial cells possess the
modulation ability which blocks T cells activation and
alleviate chronic inflammation in tissue [97]. In this
case, via the transfer of anti-inflammatory miRNAs,
MSCs release immunosuppressive exosomes, which
are actually used to treat autoimmunity disease in
clinical [98, 99].

The application of extracellular vesicles in
autoimmune diseases
Multiple Sclerosis (MS)
MS and its animal model experimental
autoimmune encephalomyelitis (EAE) is the most
common inflammatory demyelinating disease caused
by autoimmune-activated immune cells in the CNS
[100, 101]. It has been reported that EVs can penetrate
the blood-brain barrier (BBB) and contribute to brain
antigens spreading to the periphery [102]. And the
injection of microglia-derived EVs into the CNS of
EAE mice enhanced inflammation and exaggerated
disease [77]. Moreover, mice with an impaired ability
to secrete EVs were resistant to EAE [77]. Therefore,
these data indicate that EVs are involved in EAE

mechanisms. Based on the EVs roles in EAE and MS,
some groups developed treatment strategies that
employed the function of exosomes. Exosomes
(IFNγ-Exo) produced by IFNγ-stimulated MSCs have
shown a good therapeutic effect on EAE [103]. These
data provided evidence that MSCs-derived exosomes
can be used as cell-free therapies for autoimmune and
central nervous system diseases. The use of EVs
derived from overexpression of TGF-β1 dendritic cells
to EAE showed that Th1 and Th17 differentiation was
inhibited and promoted Treg production, which led to
diminished expression of EAE [104]. Casella G. et al.
designed a mouse microglial cell line that releases a
large amount of engineered EVs containing
anti-inflammatory cytokine IL-4, after injection, the
clinical score of EAE is significantly reduced [15].
Also, Zhuang et al. delivered curcumin-loaded
exosomes through a nasal route to mice with
lipopolysaccharide (LPS)-induced encephalitis and
reduced neuroinflammation by targeting microglia
[14]. In other similar LPS-induced inflammatory
demyelinating models, curcumin is also encapsulated
by exosomes, playing a role in enhancing
anti-inflammatory activity [33]. In short, regardless of
small-molecule chemical drugs, nucleotide drugs or
protein drugs, as a drug delivery system, EVs have
shown great potential for application in modern
medicine. Furthermore, Pusic A. D. et al. implied
exosomes released from bone marrow-derived
dendritic cells as a therapeutic medium that
supported the maturation of oligodendrocytes [105].
Dendritic cell-derived exosomes stimulated by low
levels of pro-inflammatory factors IFN-γ contain
higher levels of miR-219, which is vital for
oligodendrocyte
precursor
cells
(OPCs)
differentiation; meanwhile, these exosomes are
proved increase mature oligodendrocytes and
recovery the destroyed myelin in vivo. Thus, exosomes
http://www.ijbs.com
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might not only exacerbate inflammation during EAE
but may also induce myelin regeneration.

Rheumatoid Arthritis (RA)
RA is an autoimmune disease in which the
immune system reacts against the body’s cells and
tissues. Generally, synoviocytes-derived exosomes, in
inflammatory conditions like RA, stimulate
surrounding cells to secrete inflammatory mediators
for damaging cartilage [106]. It has been shown that
the use of exosomes derived from IL-10 treateddendritic cells, induced amelioration of RA severity
[54]. IL-1β-stimulated fibroblast-like synoviocytesderived EVs promoted osteoarthritic changes in
chondrocytes [107]. In RA models, EVs have exhibited
immunological abilities to induce apoptosis,
presenting antigen to T cells, and causing extracellular
damage [108]. All these pieces of evidence have
contributed to propose synovium-derived EVs as
possible biomarkers for RA [109, 110]; indeed, they
might predict disease stage and, potentially, become
relevant for building new and more effective
therapeutic approaches.
The pathogenesis of RA may be related to the
communication of EVs cell-to-cell, which involves
many complex processes such as antigen presentation
and formation of immune complexes [111],
inflammation [112, 113], destruction of extracellular
matrix [114], delivery of miRNAs [115, 116]. Withrow
J et al. and Fu H et al. reviewed in detail the research
progress of EVs in these aspects [117, 118]. It can be
concluded that EV mediates crosstalk between
immune cells, synoviocytes, endothelial cells, and
chondrocytes, thus affecting various processes of RA.
These efforts may reveal the pathogenesis of RA,
provide new insights into the targeted treatment of
RA, and new treatment opportunities, as well as
treatment strategies, may be discovered.

Type 1 diabetes (T1D)
T1D, also called diabetes mellitus type 1, is a
form of diabetes mellitus in which pancreas fails to
produce insulin. T1D is primarily a childhood
associated autoimmune disease characterized by the
destruction of insulin-producing β cells in the
pancreatic islets of Langerhans [119]. Recent work
showed that EVs may be involved in the pathogenesis
of T1D playing a role in the presentation of
autoantigen peptides from insulin-producing β cells.
For example, T lymphocytes release exosomes
containing specific microRNAs (for example,
miR-142-3p, miR-142-5p, and miR-155) that transfer
microRNAs to rodent and human pancreatic β cells,
these microRNAs triggers the expression of
chemokines in pancreatic β cells to promote apoptosis
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and result in insulin secretion disorders [120].
Exosomes also have shown potential as a therapeutic
agent in treating T1D. In particular, exosomes from
human urine-derived stem cells can prevent kidney
injury in T1D rats by the transfer of growth factors,
transforming growth factor-β1, angiogenin and bone
morphogenetic protein-7 [121]. Interestingly, studies
of MSCs have consistently shown that MSCs can
inhibit autoimmunity in T1D [122, 123]. More detailed
research data later indicated the positive effect of EVs
on these two autoimmune diseases [124].
MSC-derived EVs not only inhibits Th1 and Th17 cells
but increases the expression of immunosuppressive
cytokine IL-10, thereby effectively preventing T1D
disease development [124]. To further characterize of
exosomes, their underlying mechanisms and
relationship with different stages of the disease will
furnish the understanding of the role of exosomes in
the pathogenesis of T1D and their possible application
as therapeutic tools.

Antiphospholipid syndrome (APS)
APS is an autoimmune disease that can cause
venous or arterial thromboembolism or severe
pregnancy mortality [125]. In the last two decades,
researchers have believed that the APS pathogenesis
may be related to persistent antiphospholipid
antibodies (aPL) [126], and the main difficulty in
elucidating the pathogenesis of APS is the
heterogeneity of aPL [127]. There is strong evidence
that EVs in patients with APS are indeed elevated. It is
speculated that elevated EVs levels reflect the general
state of vascular activation. It has been reported that
EVs may stimulate thrombosis and promote vascular
activation [128]. Analysis conducted in sera of
patients affected by APS reported a significant
increase in endothelial cell-derived microvesicles
[129]. Limited experimental data indicate that aPL
stimulation can induce endothelial cells to release
specific EVs, unlike normal types, which contain IL-1β
and specific miRNA molecules. Thus, with the spread
of such EVs, the unstimulated endothelial cell was
activated by an autocrine or paracrine manner [130].
In the APS condition, EVs have shown to induce the
development of thrombosis through several
mechanisms. For example, microvesicles express a
high level of phosphatidylserine [131], and this might
facilitate the assembly of calcium-dependent
coagulation complexes and supports thrombin
generation. Further, EVs are, usually, enriched of
tissue factors and may directly support procoagulant
activity [132]. Recent evidence demonstrated that
endothelial microvesicles can interact with blood
monocytes and stimulate procoagulant activity [133].
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Systemic lupus erythematosus (SLE)
SLE is a chronic systemic autoimmune disease
that influences various organs and systems. SLE is
featured by elevated levels of pathogenic
autoantibodies, resulting in deposition of immune
complexes that cause damage to multiple systems and
organs [134, 135]. Several studies reported the
defective of apoptosis activity in SLE, leading to the
development of autoimmunity [136]. Moreover, SLE
patients exhibit an increased level of IgG-MPs in
plasma compared to controls and it correlates to
dsDNA antibodies [137]. Recent evidence suggests
that apoptosis-derived membrane vesicles from the
serum of SLE patients may activate cyclic guanosine
monophosphate (GMP)-AMP synthase (cGAS) and
stimulator of interferon genes (STING) pathway to
induce the production of IFN-I [138]. It is suggested
that blocking the cGAS-STING pathway or inhibiting
the secretion of apoptosis-derived membrane vesicles
may be a promising therapeutic target for SLE. On the
other hand, MSCs infusions technology has been used
to treat a variety of diseases. Liu's team showed that
MSCs infusions can improve bone loss in
Fas-deficient MRL/lpr mice and restore the function
of bone marrow-derived MSCs, the mechanism is that
MSCs infusions can down-regulate the intracellular
level of miR-29b by reusing Fas from MSCs
infusions-derived exosomes, thereby restoring the
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hypomethylation of the Notch1 promoter in SLE
patients, suggesting that exosomes may have clinical
therapeutic value in saving SLE secondary
osteoporosis [139].

Hashimoto thyroiditis (HT)
HT is a common autoimmune disease with an
annual incidence rate of about 1 per 1,000 people,
mainly affecting women [140]. The pathogenesis is
complex and unknown. Etiology divides HT into
primary and secondary forms [141]. The pathological
features of HT are mainly infiltration of hematopoietic
monocytes (mainly lymphocytes), destroying thyroid
cells, causing thyroid enlargement, fibrosis or other
variants [142-144]. Then clinical manifestations of
thyroid function decline or even loss [145], causing
abnormalities in the gastrointestinal system,
cardiovascular system, lung system, hematopoietic
system, and nervous system [141]. The current
research status still cannot explain the pathogenesis of
HT, and a recent work discussed whether circulating
exosomes participate in the inflammatory response of
HT. By detecting exosomes in the serum of patients, it
is indicated that these exosomes present antigen to
activate DCs, after activation, it leads to an imbalance
of CD4+ T cell differentiation, may induce HT, or will
become a breakthrough in the pathogenesis of HT
[146].

Figure 2. The application of extracellular vesicles in autoimmune diseases.
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In short, the existence of EVs is not only involved
in the development of many autoimmune diseases but
also participated in the treatment of these diseases as
a therapeutic intermediary. We have summarized
kinds of “Good” EVs that can participate in the
treatment and “Bad” EVs that promote the
development of the disease, shown in Fig. 2.

Conclusion
Research on EVs has been ardent since 2007 and
has displayed unique advantages in various fields.
EVs possess subcellular structures, which load and
may deliver a variety of molecules that participate in
many physiological processes. These pleiotropic
effects may represent a greater breakthrough in the
field of autoimmune diseases. However, the current
problem to be solved is the standardization of the
extraction and purification methods of EVs and the
more accurate and effective quantification of the
quantity or concentration of EVs. The characterization
of EVs has been plaguing researchers, and the existing
approaches are more or less flawed. With emerging
technologies that can better solve this problem,
spending more efforts to determine their origin
characteristics, and the pathogenicity role of EVs may
pave the way for new diagnostic methods. Given the
various advantages of EVs and the current research
results, we hope that EVs can also play a paramount
role in autoimmune diseases, for example, as a carrier
of therapeutic drugs or as a means of diagnosing
diseases. This review retrospects the development,
characterization, and biogenic derivation of EVs, as
well as recent research achievements on autoimmune
diseases. It is intended to provide basic ideas and
information for scholars who have entered the field.
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